These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11927800)

  • 1. Advicor (niacin extended-release and lovastatin tablets).
    Scarpa WJ
    J Clin Hypertens (Greenwich); 2002; 4(2):146. PubMed ID: 11927800
    [No Abstract]   [Full Text] [Related]  

  • 2. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
    Gupta EK; Ito MK
    Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
    Moon YS; Kashyap ML
    Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
    Bays HE
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):485-501. PubMed ID: 15225109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
    Menon R; Tolbert D; Cefali E
    Biopharm Drug Dispos; 2007 Sep; 28(6):297-306. PubMed ID: 17571283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
    Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
    Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three new drugs for hyperlipidemia.
    Med Lett Drugs Ther; 2003 Mar; 45(1151):17-9. PubMed ID: 12612501
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Bays HE; McGovern ME
    Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
    Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Nyaku M; Horvath KV; Asztalos BF; Otokozawa S; Ai M; Matthan NR; Lichtenstein AH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1672-8. PubMed ID: 18566298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia.
    Sirc J; Hrib J; Vetrik M; Hobzova R; Zak A; Stankova B; Slanar O; Hromadka R; Sandrikova V; Michalek J
    Physiol Res; 2015; 64(Suppl 1):S51-60. PubMed ID: 26447595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three new drugs for hyperlipidemia.
    Conn Med; 2003 May; 67(5):279-81. PubMed ID: 12802842
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
    Guyton JR; Fazio S; Adewale AJ; Jensen E; Tomassini JE; Shah A; Tershakovec AM
    Diabetes Care; 2012 Apr; 35(4):857-60. PubMed ID: 22338103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
    Van JT; Pan J; Wasty T; Chan E; Wu X; Charles MA
    Am J Cardiol; 2002 Jun; 89(11):1306-8. PubMed ID: 12031735
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
    Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
    Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH
    Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.